Herbals & surgery
This article was originally published in The Tan Sheet
Executive Summary
Herbal medicine use "is common among surgical patients and is consistent with the substantial increase in the use of alternative medical therapies," study published in the Journal of the American College of Surgeons says. A survey conducted by Prasad Adusumilli, MD, Memorial Sloan-Kettering Cancer Center, New York, et al., found that among patients undergoing elective surgery, 57% had used herbal medicine, 38% in the past two years, with one in six continuing herbal medicine use during the month of surgery. Doctors' awareness of patients' herbal medicine use "is important to prevent, recognize and treat potential problems that may arise from herbal medications taken alone or in conjunction with conventional medications during the perioperative period," the study states...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.